BioCentury
ARTICLE | Company News

Insilico, A2A launch Consortium.AI to develop candidates for rare orphan diseases

July 20, 2018 8:23 PM UTC

Insilico Medicine Inc. (Baltimore, Md.) and A2A Pharmaceuticals LLC (Chappaqua, N.Y.) partnered to launch Consortium.AI, a company that will use artificial intelligence to develop small molecules for rare Orphan diseases including Duchenne muscular dystrophy (DMD).

Consortium.AI will inherit computationally pre-optimized candidates against undisclosed targets selected by Insilico. A2A founder and CEO Edward Painter told BioCentury the partners are pursuing an exon-skipping therapeutic strategy in which all "the most important exons" can be targeted with a compound, rather than a single exon...